+ All Categories
Home > Documents > 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

Date post: 23-Feb-2018
Category:
Upload: viasualexandra
View: 214 times
Download: 0 times
Share this document with a friend

of 16

Transcript
  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    1/16

    Global epidemiology,detection and acces to

    therapy in EuropeIoan Sporea, MD, PhD ,

    Dept. of Gastroenterology and Hepatology,"Victor Babe" University of Medicine and Pharmacy,

    Timioara, Romania

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    2/16

    Facts Despite the fact that hepatitis C virus (HCV)

    was relatively recently discovered, it plays a central

    role in the field of hepatology.

    This is due to:

    the large number of patients infected with this virus

    around the world;

    to the fact that this infection is curable; to the development of new drugs that ensure a high

    curability of this infection.

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    3/16

    Global epidemiology of HCV infection

    in the world

    HCV infects approximately 170 million peoplearound the world (almost 3% of the entirepopulation) and 3-4 million new subjects becomeinfected each year.

    Only in the European Union there are 23 millioninfected persons, and annually 125.000

    European citizens die from complications of thischronic infection.

    WHO. Hepatitis C. Fact sheet no. 164

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    4/16

    Global epidemiology of HCV infection in the

    world (World Health Organization, Estimated global prevalence of hepatitis Cvirus infection)

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    5/16

    Epidemiology of HCV infection in Europe

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    6/16

    Epidemiology in Romania

    3,23% = possible 697.680infected persons!

    Gheorghe L. et al J Gastrointestin Liver Dis. 2010;19:373-9

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    7/16

    Epidemiology in RomaniaGheorghe L. et al J Gastrointestin Liver Dis. 2010;19(4):373-9

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    8/16

    HCV genotype in Romania

    Concerning the HCV genotype in Romania,a previous study showed a high prevalenceof genotype 1b (exceeding 99%)(1).

    But, in the last years, other genotypes werefound in Romanian people(in connectionwith a very mobile population) and thus,

    specially in young patients, the search ofthe genotype should be mandatory.

    1.Grigorescu M: JGLD 2009;18:45-50

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    9/16

    HCV genotype in Western Romania

    In a group of 253 patients with C virus chronichepatitis: 52.9% male (134), HCV genotype was

    assessed using EDTA-plasma technique

    (unpublished recent datas).

    In patients with HCV, genotype 1 dominates,

    being found in 99% of patients (250/253): 92,4 %

    (233/253) genotype 1b, 4,3 %(11/253) genotype1a and 2,3 %(6/253) genotype 1 unspecified.

    HCV genotype 3 and 4 were found only in 0.3%

    (1case) and 0.7% (2 cases) patients, respectively.

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    10/16

    IL 28B genotype in Romania

    Concerning the IL28B genotype in Romanianpopulation, a study from the Western part ofRomaniaon 107 HCV patients showed that 24.3 %were infected with C/C genotype, 62.6% with C/Tand 13.1% with T/T(1)

    The same study showed thatthe SVR rate in thiscohort (following standard of care treatment withPegInterferon and Ribavirin) was 50.5% and that it

    was directly related to the IL 28B genotype: 73.1%in the C/C genotype vs. 43.7% in non-C/C genotypes(P = 0.0126).

    1.Sporea I: Hepat Mon.2011;11(12):975-979

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    11/16

    IL 28B genotype in Romania

    Having in mind this facts, in HCV

    patients treated with Peg+Riba,evaluation of IL 28B genotype

    before the treatment, can be usefull

    for the succes of the treatment!

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    12/16

    Detection of HCV chronic infection

    Detection of HCV chronic infection is not alwayssufficient, despite a very simple and inexpensiveserological test.

    This was demonstrated by the epidemiological study

    in the "baby boomers" group or by the fact that incountries such as Germany or the United Kingdom,fewer than 40% of the infected persons aredetected!

    A better selection of the subjects suspected to beinfected, can increase the detection rate!

    1. Cornberg M et al. A systematic review of hepatitis C virus epidemiology in Europe,Canada and Israel. Liver

    International ISSN 1478-3223

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    13/16

    Detection of HCV chronic infection in

    Romania

    In Romania the detection rate of HCV infected persons isnot high enough (having in mind the high prevalence), andthis is due to the fact that only a specialist physician canprescribe the assessment of serological markers for free,and probably also because media campaigns and publicawareness are not ample enough.

    No Free and Anonymous Centers for detection

    of infected persons exist in Romania !!. A National strategy for detection of HCV chronically

    infected persons is needed, but funded with a sufficientbudget.

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    14/16

    Access to therapy

    Concerning the access to therapy in chronic

    hepatitis C patients, the world is currently divided

    in two types of countries: "rich" and "poor" ones.

    In rich countries, in the last approximately 3

    years, the standard of care (SOC) was triple

    therapy with PegInterferon +Ribavirin + Protease

    Inhibitor (PI).

    Recently, a second generation PI (Simeprevir) was

    approved in these countries.

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    15/16

  • 7/24/2019 1 Ioan Sporea__Global Epidemiology, Detection and Acces to Therapy

    16/16


Recommended